Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald M Jensen

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|April 1, 2011
A new era of hepatitis C therapy beginsDonald M Jensen
Clinics in Liver Disease|February 5, 2008
Advances in cholestatic liver disease. PrefaceDonald M Jensen
Gastroenterology & Hepatology|May 8, 2014
Advances in combination regimens in the management of HCV infectionDonald M Jensen
Therapeutic Advances in Gastroenterology|December 25, 2010
Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be Done?Donald M Jensen
Journal of Clinical Gastroenterology|July 15, 2010
Treatment duration for genotypes 2 and 3: still confusing after all these yearsDonald M Jensen
The Mount Sinai Journal of Medicine, New York|August 30, 2008
Hepatitis C: current and future therapiesPoonam Mishra, Donald M Jensen
Expert Opinion on Pharmacotherapy|October 13, 2007
Retreatment of chronic hepatitis C in previous non-responders and relapsersRohit Satoskar, Donald M Jensen
Liver International : Official Journal of the International Association for the Study of the Liver|March 28, 2009
Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cureNancy McGreal, Donald M Jensen
European Journal of Gastroenterology & Hepatology|August 12, 2005
Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirinDonald M Jensen, Patrick Marcellin
Journal of Gastroenterology and Hepatology|June 21, 2008
Ribavirin in the treatment of chronic hepatitis CPaul Martin, Donald M Jensen
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|April 1, 2011
A new era of hepatitis C therapy beginsDonald M Jensen
Clinics in Liver Disease|February 5, 2008
Advances in cholestatic liver disease. PrefaceDonald M Jensen
Gastroenterology & Hepatology|May 8, 2014
Advances in combination regimens in the management of HCV infectionDonald M Jensen
Therapeutic Advances in Gastroenterology|December 25, 2010
Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be Done?Donald M Jensen
Journal of Clinical Gastroenterology|July 15, 2010
Treatment duration for genotypes 2 and 3: still confusing after all these yearsDonald M Jensen
The Mount Sinai Journal of Medicine, New York|August 30, 2008
Hepatitis C: current and future therapiesPoonam Mishra, Donald M Jensen
Expert Opinion on Pharmacotherapy|October 13, 2007
Retreatment of chronic hepatitis C in previous non-responders and relapsersRohit Satoskar, Donald M Jensen
Liver International : Official Journal of the International Association for the Study of the Liver|March 28, 2009
Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cureNancy McGreal, Donald M Jensen
European Journal of Gastroenterology & Hepatology|August 12, 2005
Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirinDonald M Jensen, Patrick Marcellin
Journal of Gastroenterology and Hepatology|June 21, 2008
Ribavirin in the treatment of chronic hepatitis CPaul Martin, Donald M Jensen
Pageof 7